New and Emerging Treatments for Recurrent UTIs

A wave of non-antibiotic strategies for recurrent urinary tract infections is moving through clinical trials and, in some cases, into practice. These range from sublingual bacterial vaccines and vaginal probiotics to phage therapy and molecules designed to prevent bacteria from latching onto bladder cells. The shift is driven partly by rising antibiotic resistance and partly by a deeper understanding of why UTIs come back: the bacteria that cause them are remarkably good at hiding inside bladder tissue and forming protective communities that antibiotics struggle to reach. That biological reality has reshaped the research agenda, and the options patients can expect to hear about are changing fast.

Why Recurrent UTIs Resist Standard Antibiotics

Most recurrent UTIs are caused by uropathogenic E. coli, and these strains do not simply float around in urine waiting to be flushed out. They use protein structures called adhesins to bind to the cells lining the bladder, then invade those cells and multiply rapidly inside them. Once established, they form tightly packed intracellular bacterial communities that function a bit like fortified colonies, shielded from both the immune system and circulating antibiotics.¹ Some bacteria go a step further, entering a dormant state called quiescent intracellular reservoirs. These sleepers can persist for weeks without triggering an immune response, then reactivate when the bladder lining naturally turns over, sparking a new infection.²

Biofilms add another layer of protection. Bacteria embedded in biofilms are surrounded by a self-produced matrix that blocks antibiotics and immune cells from reaching them. Studies comparing E. coli strains that cause relapsing infections with those that cause new reinfections found that biofilm production was significantly more common in the relapse group, suggesting that biofilm-forming strains are the ones most likely to hunker down and persist.³ These overlapping survival strategies explain why a standard course of antibiotics can clear symptoms without actually eliminating every bacterium, setting the stage for the next episode.⁴

Vaccines That Train the Immune System

The most advanced vaccine candidate for recurrent UTIs is MV140, a sublingual preparation made from inactivated bacteria (including four species commonly responsible for UTIs). You dissolve it under the tongue daily for several months, and it works by priming the immune system to mount a faster, more targeted response when those bacteria appear in the urinary tract. A randomized, placebo-controlled trial published in NEJM Evidence found that women receiving MV140 for three or six months had a median of zero UTI episodes during the nine-month follow-up period, compared with a median of three episodes in the placebo group. Roughly twice as many women who received the vaccine stayed completely UTI-free compared to those on placebo.⁵

Real-world data from North America has echoed these results. In the first clinical experience study conducted outside Europe, the UTI rate dropped by about 75% in the nine months after vaccination, and around 80% of women reported moderate to marked improvement in their symptoms at one year.⁶ A related approach uses personalized autovaccines made from bacteria isolated from the patient’s own urine. A Spanish pilot study of this approach found that UTI episodes fell from nearly four per year before treatment to about one per year after, and the effect was strongest at three months post-treatment, when the vast majority of patients had no episodes at all.⁷

A different immunotherapy product, an oral E. coli extract called Uro-Vaxom, has been available in parts of Europe and Asia for longer. It works by stimulating immune defenses in a different way, including boosting levels of the antibody IgA in urine and activating certain immune cells.⁸ Uro-Vaxom has been studied for decades with generally modest benefits, while MV140 appears to produce stronger effects in head-to-head comparisons of trial data. Neither is yet approved by the FDA, but MV140 in particular is generating substantial interest as larger confirmatory trials proceed.

Vaginal Estrogen and the Microbiome

For postmenopausal women, one of the most effective existing interventions is not new at all, but it remains underused and is still generating fresh research. After menopause, declining estrogen levels cause the vaginal lining to thin and become less acidic, and protective Lactobacillus bacteria tend to disappear. This shift allows UTI-causing bacteria to thrive near the urethra. A landmark controlled trial found that intravaginal estriol cream slashed UTI rates from nearly six episodes per year to about half an episode per year. Within a month of treatment, Lactobacillus bacteria reappeared in over 60% of women using estriol and in none of the placebo group, while vaginal pH dropped from 5.5 to 3.8.⁹

More recent research has gone deeper, using genomic tools to examine exactly how vaginal estrogen reshapes the urinary and vaginal microbiome. One study found that specific species of Lactobacillus responded differently to estrogen therapy, and that a bloom of L. crispatus in particular was associated with successful treatment.¹⁰ This kind of work is nudging the field toward a more precise understanding of which microbial shifts actually prevent infection, rather than treating all Lactobacillus as interchangeable.

Blocking Bacteria From Sticking to the Bladder

Since bacterial adhesion to bladder cells is the first step in establishing an infection, one logical strategy is to develop molecules that physically prevent that attachment. The main target is a protein called FimH, found on the tips of tiny hair-like structures (type 1 pili) that E. coli uses to grip bladder cells. Researchers have designed synthetic compounds called mannosides that fit snugly into FimH’s binding site, effectively jamming the lock so the bacterium cannot attach. In lab studies using human bladder cells, these mannosides reduced the number of bacteria that adhered by more than 90% at higher concentrations, with the most potent compound working at extremely low doses.¹¹ Earlier preclinical work showed these mannosides could be given orally and were effective at preventing colonization, invasion, and the formation of those troublesome intracellular bacterial communities discussed above.¹² FimH inhibitors are still in the pipeline and have not yet reached late-stage human trials, but they represent one of the more conceptually elegant approaches because they target the infection’s very first foothold.

A far simpler version of this idea involves D-mannose, a sugar that occurs naturally and can be taken as a supplement. The concept is similar: D-mannose molecules can bind to FimH and theoretically prevent bacteria from attaching to the bladder wall.¹³ One oft-cited randomized trial found that D-mannose powder reduced recurrent UTI rates comparably to the antibiotic nitrofurantoin, with both groups faring far better than a no-treatment group.¹⁴ However, an updated meta-analysis that pooled results from multiple trials found that D-mannose did not significantly reduce the risk of recurrent UTIs in adult women overall.¹⁵ The evidence, in other words, is genuinely mixed. D-mannose is safe and widely available, and some women report clear benefits, but it should not be viewed as a proven replacement for other prevention strategies.

Cranberry products work through a related but distinct mechanism. The active compounds in cranberries, proanthocyanidins, block a different type of bacterial adhesin from binding to bladder cells.¹⁶ The evidence for cranberries is a bit like the evidence for D-mannose: some trials show benefit, others do not. The Cochrane review on the topic reflects this inconsistency. If you find cranberry supplements helpful, they are unlikely to cause harm, but they are not a substitute for more proven approaches if your infections are frequent or severe.

Bacteriophage Therapy

Phage therapy uses viruses that naturally prey on bacteria. Each phage targets a narrow range of bacterial strains, killing them without harming human cells or disrupting the broader microbiome the way antibiotics do. For UTIs specifically, phages have a potential advantage: they can penetrate and break apart the biofilms that protect bacteria inside the bladder.¹⁷

A comprehensive systematic review found preliminary evidence supporting phage therapy as safe and potentially effective for UTIs, though the studies reviewed were mostly small case reports and early-stage trials rather than large randomized controlled trials.¹⁸ Synthesized data from recurrent UTI cohorts suggest that roughly 70 to 80% of patients achieve clinical improvement, though success depends heavily on matching the phage precisely to the patient’s specific bacterial isolate.¹⁹ That matching requirement is both phage therapy’s strength and its main logistical hurdle. It works best as personalized medicine, and scaling that up into routine clinical use requires infrastructure for rapidly testing each patient’s bacteria against a library of available phages. For patients with multidrug-resistant infections who have exhausted antibiotic options, phage therapy is already being used on a compassionate-use basis at specialized centers.

Probiotics and Fecal Microbiota Transplantation

If the vaginal microbiome matters for UTI prevention, as the estrogen data strongly suggest, then directly introducing protective bacteria is a logical next step. The most studied candidate is Lactin-V, a vaginal suppository containing a specific strain of Lactobacillus crispatus. In a phase 2 trial, recurrent UTIs occurred in about 15% of women receiving Lactin-V compared with 27% on placebo. Women who achieved and maintained high levels of vaginal L. crispatus colonization had a dramatic reduction in recurrence.²⁰ Follow-up work confirmed that the probiotic strain colonized effectively in virtually all recipients during treatment, with L. crispatus making up over 90% of the vaginal bacteria at every visit in the active group, and colonization persisted in most women for at least two months after stopping the suppositories.²¹ Larger confirmatory trials are underway.

An even more novel microbiome approach involves fecal microbiota transplantation. The reasoning is that the gut is the primary reservoir for E. coli strains that go on to cause UTIs, so resetting the gut microbiome might cut off the supply. Early results are intriguing but preliminary. One proof-of-concept study found a 68% reduction in UTI episodes over six months after fecal transplant, along with elimination of multidrug-resistant bacteria from stool.²² A separate pilot study reported that the decrease in UTIs did not reach statistical significance, but several women who had been having constant infections stopped meeting criteria for recurrent UTI altogether, with no serious side effects.²³ A more recent cohort study likewise found fecal transplant associated with resolution of recurrent UTI and reduced infection frequency.²⁴ These are small, early-stage studies, and fecal transplant for UTIs remains experimental. But for patients with resistant organisms who have run out of antibiotic options, it is an area to watch.

Bladder Instillations

Rather than taking a drug by mouth and waiting for it to reach the bladder through the bloodstream, instillation therapy delivers treatment directly into the bladder via a catheter. Two main approaches are being studied. The first uses glycosaminoglycans, natural components of the bladder’s protective lining. The idea is that restoring this barrier makes it harder for bacteria to adhere and invade. A randomized trial found that instillations of hyaluronic acid and chondroitin sulfate reduced UTI rates by about 87% compared to less than 10% for placebo, and the time between infections roughly tripled.²⁵ A European multicentre study found that treated patients had about half the risk of a confirmed recurrence within 12 months compared to standard care alone.²⁶

The second approach uses aminoglycoside antibiotics instilled directly into the bladder, which keeps the drug concentration high at the site of infection while avoiding the systemic side effects of oral or intravenous antibiotics. A meta-analysis found that aminoglycoside instillations produced a substantial reduction in UTI recurrence, with blood levels of the drug undetectable where measured and adverse events mild and uncommon.²⁷ This approach is especially appealing for people with neurogenic bladder conditions who already catheterize regularly, since the instillation can be combined with their existing routine.

Methenamine Hippurate

Methenamine hippurate is an old drug that has been getting renewed attention. It works by converting to formaldehyde in acidic urine, creating a hostile environment for bacteria without being a traditional antibiotic and therefore without driving resistance in the same way. An updated meta-analysis with trial sequential analysis found that methenamine was non-inferior to prophylactic antibiotics for preventing symptomatic UTI episodes.²⁸ In practical terms, it works about as well as daily low-dose antibiotics for keeping UTIs at bay but avoids the resistance problems associated with long-term antibiotic use. It is already available by prescription in many countries and is worth discussing with a doctor if you are currently on antibiotic prophylaxis and would prefer a non-antibiotic alternative.

The Antibiotic Resistance Problem

Understanding why so many of these emerging approaches matter requires grasping the scale of resistance being generated by current practices. The standard approach for years has been to give patients a low daily dose of antibiotics to prevent recurrences. This does reduce infections while you are taking the pills, but a randomized trial found that resistance to common UTI antibiotics increased significantly within nine to twelve months of prophylaxis. Resistance to trimethoprim, for instance, was found in urinary isolates from about two-thirds of the prophylaxis group compared to about a third of the control group.²⁹ The gut serves as a reservoir for both resistant and sensitive E. coli strains, meaning that resistance selected under prophylaxis does not just affect the individual patient but can complicate future treatment and spread within communities.³⁰ This is the backdrop against which every non-antibiotic strategy described in this article gains urgency.

Advanced Diagnostics

Better treatments work best when paired with better diagnosis. Standard urine cultures miss a surprising amount. They are designed to detect common bacteria at high concentrations, but recurrent UTIs can involve unusual organisms, mixed infections, or bacteria present at levels below the culture threshold. Metagenomic next-generation sequencing, which reads all the genetic material in a urine sample, has shown dramatically higher detection rates. In one study of kidney transplant recipients with recurrent UTIs, sequencing identified a pathogen in every single sample compared to about a third for standard culture. It also detected viruses and fungi that culture missed entirely, and it flagged mixed infections in nearly 90% of cases where culture found a single organism or nothing at all.³¹ This kind of testing is still expensive and mostly used in complex or refractory cases, but as costs come down it could reshape how recurrent UTIs are diagnosed and treated in routine practice.

When Infections Leave a Mark on the Bladder Itself

One emerging area of research that often surprises patients is the discovery that recurrent infections can cause lasting changes to the bladder, even after the bacteria are cleared. Animal research has shown that repeated UTIs trigger nerve growth factor release, which drives new sensory nerve fibers to sprout into the bladder wall. Combined with chronic activation of mast cells (immune cells involved in inflammation), this nerve sprouting appears to produce ongoing pain and bladder dysfunction that persist independently of any active infection.³² This finding helps explain why some people with a history of recurrent UTIs continue to experience urgency, frequency, and pelvic pain even between infections. It also suggests that treating recurrent UTIs aggressively and early, rather than waiting through repeated cycles, might prevent these longer-term neurological changes from setting in. Research into mast cell stabilizers and nerve-targeted therapies for this aspect of the problem is still in early stages but represents a genuinely different frontier from simply killing bacteria.

Anatomical Factors and Surgical Correction

Not every case of recurrent UTI is purely a problem of microbiology. In some women, pelvic organ prolapse leads to incomplete bladder emptying, which creates a standing pool of urine where bacteria thrive. When the anatomical issue is corrected surgically, the infections often stop. One surgical series found that recurrent UTIs ceased in over 86% of patients who had prolapse repair, along with improvements in incontinence and quality of life.³³ Genetic factors also play a role in who is susceptible. A systematic review identified several genes involved in immune signaling and bacterial recognition that appear to be associated with increased risk of recurrent UTIs, pointing toward innate differences in how efficiently some people’s immune systems detect and respond to bacteria in the urinary tract.³⁴ These individual differences help explain why two people with similar habits and hygiene can have vastly different UTI histories, and they underscore that recurrent UTIs are a medical condition, not a personal failing.